| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Molecular Biology Laboratory, National Cancer Research Institute (IST), Genova, Italy; and
* Department of Health Sciences, Section of Hygiene and Preventive Medicine, University of Genova, Italy
1Correspondence: Molecular Biology Laboratory, Istituto Nazionale per la Ricerca sul Cancro (IST), c/o Centro di Biotecnologie Avanzate, Largo Rosanna Benzi, n.10, 16132 Genova, Italy. E-mail: albini{at}cba.unige.it
The potential to block tumor growth by inhibition of the neoangiogenic process represents an intriguing approach to the treatment of solid tumors. The high proliferation rate in the tumor deprived of proper vascularization would be balanced by cell death due to lack of diffusion of nutrients and oxygen. Matrix metalloproteinases (MMPs), angiogenic growth factors, and their receptors are the main targets of an increasing number of clinical trials approved to test the tolerance and therapeutic efficacy of antiangiogenic agents. We observed that a series of substances proposed as possible cancer chemopreventive agents show antiangiogenic properties when tested in in vitro and in vivo angiogenesis models. We demonstrated that N-acetyl-L-cysteine is able to reduce the invasive and metastatic potential of melanoma cells, and to inhibit endothelial cell invasion by direct inhibition of MMP activity. We also showed that epigallocatechin gallate (EGCG), a flavonoid from green tea that possesses chemopreventive activity in experimental and epidemiological studies, is a potent inhibitor of MMP-2 and MMP-9. Angiogenesis has also been demonstrated to be a target for nonsteroidal anti-inflammatory drug chemopreventive activity. Based on these data, we hypothesize that other chemopreventive agents, including natural or synthetic retinoids, steroid hormone antagonists, peroxisome proliferator-activated receptor 
ligands, vitamin D, and protease inhibitors, might have antiangiogenesis as an important mechanism of action, a novel concept we will term ‘angioprevention’. We analyze the mechanisms on how and why chemopreventive agents could exert antiangiogenic effects aimed at controlling tumor growth, and their potential use in the clinic.—Tosetti, F., Ferrari, N., De Flora, S., Albini, A. ‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents.
Key Words: antiangiogenesis • chemoprevention • steroids • retinoids • flavonoids • thiols • protease inhibitors • NSAIDs.
This article has been cited by other articles:
|
|
 |
|
  H. Sun, W.-C. Chung, S.-H. Ryu, Z. Ju, H. T. Tran, E. Kim, J. M. Kurie, and J. S. Koo Cyclic AMP-Responsive Element Binding Protein- and Nuclear Factor-{kappa}B-Regulated CXC Chemokine Gene Expression in Lung Carcinogenesis Cancer Prevention Research, October 1, 2008; 1(5): 316 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Vannini, G. Lorusso, R. Cammarota, M. Barberis, D. M. Noonan, M. B. Sporn, and A. Albini The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent Mol. Cancer Ther., December 1, 2007; 6(12): 3139 - 3146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beliveau and D. Gingras Role of nutrition in preventing cancer Can Fam Physician, November 1, 2007; 53(11): 1905 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Albini, D. M. Noonan, and N. Ferrari Molecular Pathways for Cancer Angioprevention Clin. Cancer Res., August 1, 2007; 13(15): 4320 - 4325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Larghero, R. Vene, S. Minghelli, G. Travaini, M. Morini, N. Ferrari, U. Pfeffer, D. M. Noonan, A. Albini, and R. Benelli Biological assays and genomic analysis reveal lipoic acid modulation of endothelial cell behavior and gene expression Carcinogenesis, May 1, 2007; 28(5): 1008 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dell'Eva, C. Ambrosini, S. Minghelli, D. M. Noonan, A. Albini, and N. Ferrari The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-{kappa}B pathway Carcinogenesis, February 1, 2007; 28(2): 404 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Lee, E.-O. Lee, Y.-H. Rhee, K. S. Ahn, G.-X. Li, C. Jiang, J. Lu, and S.-H. Kim An oriental herbal cocktail, ka-mi-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis and metastasis Carcinogenesis, December 1, 2006; 27(12): 2455 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tosetti, D. M. Noonan, and A. Albini Choking hypoxia-inducible factor 1alpha: a novel mechanism for connective tissue growth factor inhibition of angiogenesis. J Natl Cancer Inst, July 19, 2006; 98(14): 946 - 948. [Full Text] [PDF]
|
|
|
|
|
|
A. Albini and U. Pfeffer A new tumor suppressor gene: invasion, metastasis, and angiogenesis as potential key targets. J Natl Cancer Inst, June 21, 2006; 98(12): 800 - 801. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schindler and R. Mentlein Flavonoids and Vitamin E Reduce the Release of the Angiogenic Peptide Vascular Endothelial Growth Factor from Human Tumor Cells J. Nutr., June 1, 2006; 136(6): 1477 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bertl, H. Bartsch, and C. Gerhauser Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol. Cancer Ther., March 1, 2006; 5(3): 575 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Albini, F. Tosetti, R. Benelli, and D. M. Noonan Tumor Inflammatory Angiogenesis and Its Chemoprevention Cancer Res., December 1, 2005; 65(23): 10637 - 10641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ferrari, U. Pfeffer, R. Dell'Eva, C. Ambrosini, D. M. Noonan, and A. Albini The Transforming Growth Factor-{beta} Family Members Bone Morphogenetic Protein-2 and Macrophage Inhibitory Cytokine-1 as Mediators of the Antiangiogenic Activity of N-(4-Hydroxyphenyl)Retinamide Clin. Cancer Res., June 15, 2005; 11(12): 4610 - 4619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nakagawa, A. Kawaura, S. Kato, E. Takeda, and T. Okano 1{alpha},25-Dihydroxyvitamin D3 is a preventive factor in the metastasis of lung cancer Carcinogenesis, February 1, 2005; 26(2): 429 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Vucenik, A. Passaniti, M. I. Vitolo, K. Tantivejkul, P. Eggleton, and A. M. Shamsuddin Anti-angiogenic activity of inositol hexaphosphate (IP6) Carcinogenesis, November 1, 2004; 25(11): 2115 - 2123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Levine and D. Teegarden 1{alpha},25-Dihydroxycholecalciferol Increases the Expression of Vascular Endothelial Growth Factor in C3H10T1/2 Mouse Embryo Fibroblasts J. Nutr., September 1, 2004; 134(9): 2244 - 2250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. K. Lee, N. D. Bone, A. K. Strege, T. D. Shanafelt, D. F. Jelinek, and N. E. Kay VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia Blood, August 1, 2004; 104(3): 788 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Johnson, H.-J. Sung, S. M. Lessner, M. E. Fini, and Z. S. Galis Matrix Metalloproteinase-9 Is Required for Adequate Angiogenic Revascularization of Ischemic Tissues: Potential Role in Capillary Branching Circ. Res., February 6, 2004; 94(2): 262 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ferrari, M. Morini, U. Pfeffer, S. Minghelli, D. M. Noonan, and A. Albini Inhibition of Kaposi's Sarcoma in Vivo by Fenretinide Clin. Cancer Res., December 1, 2003; 9(16): 6020 - 6029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Favot, S. Martin, T. Keravis, R. Andriantsitohaina, and C. Lugnier Involvement of cyclin-dependent pathway in the inhibitory effect of delphinidin on angiogenesis Cardiovasc Res, August 1, 2003; 59(2): 479 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Pfeffer, D. Noonan, and A. Albini Re: Microarray Studies Challenge Theories of Metastasis J Natl Cancer Inst, June 4, 2003; 95(11): 829 - 829. [Full Text] [PDF]
|
|
|
|
|
|
M. Matsuo, H. Sakurai, and I. Saiki ZD1839, a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Shows Antimetastatic Activity Using a Hepatocellular Carcinoma Model Mol. Cancer Ther., June 1, 2003; 2(6): 557 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tosetti, R. Vene, G. Arena, M. Morini, S. Minghelli, D. M. Noonan, and A. Albini N-(4-Hydroxyphenyl)retinamide Inhibits Retinoblastoma Growth through Reactive Oxygen Species-Mediated Cell Death Mol. Pharmacol., March 1, 2003; 63(3): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Heidemann, H. Ogawa, M. B. Dwinell, P. Rafiee, C. Maaser, H. R. Gockel, M. F. Otterson, D. M. Ota, N. Lugering, W. Domschke, et al. Angiogenic Effects of Interleukin 8 (CXCL8) in Human Intestinal Microvascular Endothelial Cells Are Mediated by CXCR2 J. Biol. Chem., February 28, 2003; 278(10): 8508 - 8515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cheng, H. Huang, J. Pak, E. Shapiro, T.-T. Sun, C. Cordon-Cardo, F. M. Waldman, and X.-R. Wu Allelic Loss of p53 Gene Is Associated with Genesis and Maintenance, but not Invasion, of Mouse Carcinoma in Situ of the Bladder Cancer Res., January 1, 2003; 63(1): 179 - 185. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
